Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Cel-Sci Corp (CVM)

Cel-Sci Corp (CVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Have a Relaxing Holiday Season Baystreet - Fri Dec 20, 2:13PM CST

Monday U.S. Economic Lookahead Consumer confidence (Dec.) Featured Earnings Limoneira ...

OTLK : 1.4400 (+3.60%)
PFX : 49.70 (+0.61%)
LMNR : 26.30 (+2.49%)
CVM : 0.7299 (-4.60%)
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector BayStreet.ca - Thu Dec 19, 12:59PM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite significant advances in oncology research, challenges remain as the American Cancer Society...

ONCY : 0.8310 (-6.36%)
PYXS : 1.6900 (+9.74%)
RPTX : 1.3200 (unch)
IMRX : 2.00 (+8.70%)
CVM : 0.7299 (-4.60%)
ONC.TO : 1.19 (-9.16%)
Goodbye ’23 Baystreet - Fri Dec 22, 2023

Monday U.S. and Canada Christmas Day, Markets Closed Tuesday U.S. Economic ...

CVM : 0.7299 (-4.60%)
CTXR : 2.60 (+1.17%)
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments FinancialNewsMedia - Tue Oct 24, 2023

EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END

TCBP : 0.6600 (+0.15%)
CVM : 0.7299 (-4.60%)
INVO : 0.8330 (-2.91%)
SNY : 47.71 (+0.44%)
PFE : 26.36 (+2.29%)
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock Business Wire - Thu Apr 27, 2023

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of its underwritten confidentially marketed public...

CVM : 0.7299 (-4.60%)
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer Business Wire - Wed Apr 19, 2023

CEL-SCI Corporation (NYSE American: CVM) today announced it has held a productive pre-submission meeting with Canada’s regulator to determine the best regulatory path toward market approval. Based...

CVM : 0.7299 (-4.60%)
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension Business Wire - Wed Mar 8, 2023

CEL-SCI Corporation (NYSE American: CVM) today reported new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head...

CVM : 0.7299 (-4.60%)
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology Business Wire - Fri Mar 3, 2023

CEL-SCI Corporation (NYSE American: CVM) today announced it will present new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma...

CVM : 0.7299 (-4.60%)
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results Business Wire - Wed Feb 15, 2023

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2022, as well as key clinical and corporate developments.

CVM : 0.7299 (-4.60%)
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments Business Wire - Wed Dec 28, 2022

CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2022, as well as key clinical and corporate developments.

CVM : 0.7299 (-4.60%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot